Biologics in severe asthma: the role of real-world evidence from registries

Giovanni Paoletti, Jack Pepys, Marta Casini, Danilo Di Bona, Enrico Heffler, Celine Y.Y. Goh, David B. Price, Giorgio Walter Canonica*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

1 Citation (Scopus)
1 Downloads (Pure)


Asthma is one of the most common noncommunicable diseases; in the majority of patients it is well controlled with inhaled bronchodilators and inhaled corticosteroids, but the management of severe asthma has been a significant challenge historically. The introduction of novel biologic drugs in the past few decades has revolutionised the field, presenting physicians with a variety of biologic drugs with different mechanisms for the treatment of severe asthma. It is of crucial importance to evaluate the effectiveness of these drugs by following their “real-life” effectiveness rather than relying solely on their efficacy, established in carefully designed clinical trials, which therefore do not necessarily match the profile of the real-life patient. Understanding the actual effectiveness of the specific drugs in real-life patients is a crucial part of tailoring the right drugs to the right patients. Registries serve as an important tool in obtaining real-life evidence, since they are in effect observational studies, following the entire patient population.

Original languageEnglish
Article number210278
Number of pages11
JournalEuropean Respiratory Review
Issue number164
Early online date7 Jun 2022
Publication statusPublished - 30 Jun 2022


Dive into the research topics of 'Biologics in severe asthma: the role of real-world evidence from registries'. Together they form a unique fingerprint.

Cite this